UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus

International journal of antimicrobial agents, 2016-11, Vol.48 (5), p.528-534

2016

Volltextzugriff (PDF)

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Antimicrobial Agents and Chemotherapy, 2005-09, Vol.49 (9), p.3944-3947

2005

Volltextzugriff (PDF)

Correction of a Reference to Clinical Laboratory Standards Institute Interpretive Criteria

Clinical infectious diseases, 2008-06, Vol.46 (11), p.1798-1798

2008

Volltextzugriff (PDF)

In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

Antimicrobial Agents and Chemotherapy, 2005-06, Vol.49 (6), p.2510-2511

2005

Volltextzugriff (PDF)

In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

Antimicrobial Agents and Chemotherapy, 2004-04, Vol.48 (4), p.1384-1396

2004

Volltextzugriff (PDF)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Infectious diseases and therapy, 2016-09, Vol.5 (3), p.353-361

2016

Volltextzugriff (PDF)

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains

Diagnostic microbiology and infectious disease, 2008-09, Vol.62 (1), p.110-112

2008

Volltextzugriff (PDF)

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Clinical infectious diseases, 2015-01, Vol.60 (2), p.254-262

2015

Volltextzugriff (PDF)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Infectious diseases and therapy, 2016-09, Vol.5 (3), p.363-365

2016

Volltextzugriff (PDF)

Comparing Gatifloxacin and Clarithromycin in Pneumonia Symptom Resolution and Process of Care

Antimicrobial Agents and Chemotherapy, 2006-04, Vol.50 (4), p.1164-1169

2006

Volltextzugriff (PDF)

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis

Clinical therapeutics, 2002-06, Vol.24 (6), p.906-917

2002

Volltextzugriff (PDF)

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study

Diagnostic microbiology and infectious disease, 2002-09, Vol.44 (1), p.85-91

2002

Volltextzugriff (PDF)

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin

Otolaryngology-head and neck surgery, 2002-09, Vol.127 (3), p.182-189

2002

Volltextzugriff (PDF)

1331The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Open forum infectious diseases, 2014-12, Vol.1 (suppl_1), p.S55-S55

2014

Volltextzugriff (PDF)

685Time to Onset and Duration of Adverse Events in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Oritavancin – The SOLO Studies

Open forum infectious diseases, 2014-12, Vol.1 (suppl_1), p.S194-S194

2014

Volltextzugriff (PDF)

A multicenter, open-label, randomized study comparing gatifloxacin vs clarithromycin and ceftriaxone for treatment of community-acquired pneumonia

Chest, 2004-10, Vol.126 (4), p.847S-847S

2004

Volltextzugriff (PDF)

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study : Symposium on the topic of gatifloxacin (TeqCES trial)

Diagnostic microbiology and infectious disease, 2002, Vol.44 (1), p.85-91

2002

Volltextzugriff (PDF)

FDA and the Antibiotic Breakpoint Updating Process

Microbe (Washington, D.C.), 2007-07, Vol.2 (7), p.321-322

2007

Volltextzugriff (PDF)

P74. tDCS Augmentation of Voluntary Neuromodulation in Healthy Adults

Biological psychiatry (1969), 2022-05, Vol.91 (9), p.S117-S117

2022

Volltextzugriff (PDF)

The Impact of Experience with a Family Member with Alzheimer’s Disease on Views about the Disease across Five Countries

International journal of alzheimer's disease, 2012, Vol.2012, p.903645-9

2012

Volltextzugriff (PDF)

Five-country survey of public experiences, attitudes and beliefs concerning Alzheimer's disease and the value of a diagnosis

Alzheimer's & dementia, 2011-07, Vol.7 (4), p.e50-e50

2011

Volltextzugriff (PDF)

P4‐395: Five‐country survey of public experiences, attitudes and beliefs concerning Alzheimer's disease and the value of a diagnosis

Alzheimer's & dementia, 2011-07, Vol.7 (4S_Part_25), p.e50-e50

2011

Volltextzugriff (PDF)

Altered standards of care during an influenza pandemic: identifying ethical, legal, and practical principles to guide decision making

Disaster medicine and public health preparedness, 2009-12, Vol.3 Suppl 2 (S2), p.S132-S140

2009

Volltextzugriff (PDF)

The effect of intrahypothalamic microinjection of hemicholinium (HC-3) on the hippocampal theta rhythm of cats

Psychopharmacologia, 1970, Vol.17 (4), p.345-353

1970

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(24)
magazinearticle
(1)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Humans
(10)
Microbiology
(9)
Microbial Sensitivity Tests
(8)
Aged
(7)
Biological And Medical Sciences
(7)
Female
(7)
Infectious Diseases
(7)
Male
(7)
Medical Sciences
(7)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Adult
(6)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(6)
Pharmacology. Drug Treatments
(6)
Anti-Bacterial Agents - Pharmacology
(4)
Fluoroquinolones
(4)
Treatment Outcome
(4)
Adolescent
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Correction of a Reference to Clinical Laboratory Standards Institute Interpretive Criteria

In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains

Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

Comparing Gatifloxacin and Clarithromycin in Pneumonia Symptom Resolution and Process of Care

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin

1331The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

685Time to Onset and Duration of Adverse Events in Patients with Acute Bacterial Skin and Skin Structure Infections Treated with Oritavancin – The SOLO Studies

A multicenter, open-label, randomized study comparing gatifloxacin vs clarithromycin and ceftriaxone for treatment of community-acquired pneumonia

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study : Symposium on the topic of gatifloxacin (TeqCES trial)

FDA and the Antibiotic Breakpoint Updating Process

P74. tDCS Augmentation of Voluntary Neuromodulation in Healthy Adults

The Impact of Experience with a Family Member with Alzheimer’s Disease on Views about the Disease across Five Countries

Five-country survey of public experiences, attitudes and beliefs concerning Alzheimer's disease and the value of a diagnosis

P4‐395: Five‐country survey of public experiences, attitudes and beliefs concerning Alzheimer's disease and the value of a diagnosis

Altered standards of care during an influenza pandemic: identifying ethical, legal, and practical principles to guide decision making

The effect of intrahypothalamic microinjection of hemicholinium (HC-3) on the hippocampal theta rhythm of cats

Suchergebnisse filtern